Sign up to save your podcasts
Or
Share 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
View all episodes
By STAT
4.5
304304 ratings
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
More shows like The Readout Loud
View all
Planet Money
30,845 Listeners
a16z Podcast
1,040 Listeners
Odd Lots
1,789 Listeners
KFF Health News' 'What the Health?'
478 Listeners
The Long Run with Luke Timmerman
122 Listeners
Talks at GS
84 Listeners
The Journal.
5,942 Listeners
Tradeoffs
391 Listeners
Biotech 2050 Podcast
59 Listeners
BioCentury This Week
29 Listeners
Hard Fork
5,462 Listeners
Raising Health
147 Listeners
Biotech Hangout
18 Listeners
Ground Truths
51 Listeners
Money Stuff: The Podcast
371 Listeners